Revised Trading Statement for the year ended 30 June 2021
Revised Trading Statement for the year ended 30 June 2021 Ascendis Health Limited (Registration number 2008/005856/06) (Incorporated in the Republic of South Africa) Share code: ASC ISIN: ZAE000185005 (“Ascendis Health” or “the Company”) REVISED TRADING STATEMENT FOR THE YEAR ENDED 30 JUNE 2021 Shareholders are referred to the trading statement released by the Company on SENS on 20 September 2021 (“First Trading Statement”) setting out its expected performance for the year ended 30 June 2021 (“current period”) in relation to that of the corresponding comparative year ended 30 June 2020 (“comparative period”). Shareholders are advised that the finalisation of certain year end and audit procedures has resulted in the following adjustments: - the restated comparative figures provided in the First Trading Statement for the comparative period have been revised, impacting the percentage and quantum of movements disclosed in the First Trading Statement; and - the headline earnings per share and normalised headline earnings per share estimates for total operations for the current period has been revised. There are no changes to the current year continuing operations amounts. Shareholders should refer to the below revised expected financial performance: Continuing Operations Total Operations Cents per share FY2021 FY2020 % increase / FY2021 FY2020 % increase / (Restated) (decrease) in (Restated) (decrease) in loss loss Basic loss per Share 308.5 – 371.4 316.7* (3%) - 17% 204.5 - 244.6 202.3* 1% - 21% Headline loss per share 300.9 – 346.4 229.4* 31% - 51% 111.4 – 119.1* 38.9* 186% - 206% Normalised headline 251.9 – 290.4 193.7* 30% - 50% 25.3 – 26.6* (6.5)* 490%- 510% loss/(profit) per share *Revised from First Trading Statement. As noted in the First Trading Statement, the restatement of prior year results is driven by, inter alia, the requirements of IFRS 5: Non-current assets held for sale and discontinued operations, which requires the comparative results for discontinued operations to be restated. Further revised details on the figures which comprise the restatements of prior year comparative information will be provided in the detailed results announcement which will be published by the Company on 30 September 2021. This trading statement and operational update is the responsibility of the directors and the financial information on which this statement is based has not been reviewed or reported on by the external auditors. 29 September 2021 Bryanston Sponsor Questco Corporate Advisory Proprietary Limited PM1 - Normalised EBITDA, Normalised headline earnings and normalised headline earnings per share are alternative performance measures or non-IFRS measures. Further details regarding the computation of the performance measures and its purpose can be found on the Company’s website via: : https://ascendishealth.com/wp- content/uploads/2020/09/Ascendis-Health-PerformanceMeasures-30-June-2020.pdf Date: 29-09-2021 03:12:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.